Lytgobi

FDA
Marketing

FDA calls out 'concerning' claims on site for Taiho's Lytgobi

In an untitled letter made public this week, the FDA took aim at clinical data included on a doctor-facing web page for Taiho Oncology’s Lytgobi.
Andrea Park Mar 26, 2025 1:21pm
FDA

A third FGFR inhibitor is wading into the bile duct cancer arena

Oct 3, 2022 10:30am